Loading
A phase 1/2 trial of Cemiplimab in prostate cancer and renal cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT07594106 by Regeneron Pharmaceuticals, with 265 participants planned, started 2026-07-20 and due to reach its primary completion in 2030-10-27. Interventions recorded: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC). No results are recorded here; the registry entry is the source.
Shares Regeneron, Cemiplimab, Metastatic castration-resistant prostate cancer, Renal cell carcinoma.
Shares Regeneron, Cemiplimab, Renal cell carcinoma, Immune checkpoint inhibitors.
Shares Regeneron, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Immune checkpoint inhibitors.